MARSEILLE, France--(BUSINESS WIRE)--October 20, 2026-- 

Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announces that the Company will hold a conference call on Thursday, November 5, 2026, at 2 p.m. CET / 8 a.m. ET, to provide a business and financial update for the third quarter of 2026.

Participants during the call will be:

   --  Jonathan Dickinson, Chief Executive Officer 
 
   --  Markus Jensen, Vice President, Chief Medical Officer 
 
   --  Yannis Morel, Executive Vice President, Chief Operating Officer 
 
   --  Stéphanie Cornen, Vice President, Investor Relations and 
      Communications 
 
   --  Frédéric Lombard, Senior Vice President, Chief Financial 
      Officer 

Event details

   --  Date and time: November 5, 2026 at 2:00 p.m. CET / 8:00 a.m. ET 
 
   --  Webcast link: Click here 
 
   --  Conference call link: Click here 

This information is also available on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for cutaneous T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.

Headquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

 
ISIN code      FR0010331421 
 Ticker code    Euronext: IPH Nasdaq: IPHA 
 LEI            9695002Y8420ZB8HJE29 
 

Disclaimer on forward-looking information and risk factors

For a discussion of risks and uncertainties, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website (www.amf-france.org) or on Innate Pharma's website , including the Company's Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261019551853/en/

 
    CONTACT:    Stéphanie Cornen 

stephanie.cornen@innate-pharma.fr

Investor Relations

investors@innate-pharma.fr

Media

communication@innate-pharma.fr